Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Licenses OmniRat Antibody | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer Licenses OmniRat Antibody

Will use OMT’s platform for antibody R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Open Monoclonal Technology (OMT) and Pfizer have entered an agreement under which Pfizer will use OMT’s OmniRat for antibody R&D. OmniRat is a platform technology that generates fully human antibodies and enables developers to skip humanization of animal-derived antibodies or lead optimization of display candidates.
 
Dr. Roland Buelow, founder and chief executive officer of OMT, said, “OMT is pleased that Pfizer’s testing of our antibody platform showed that OmniRat makes antibodies just like normal rats and covers different epitopes than mice. OMT and Pfizer have performed in-depth characterization of OmniRat and generated antibodies binding to several different targets with subnanomolar affinities.”
 
Dr. Jaume Pons, chief scientific officer of Pfizer’s Rinat Laboratories, added, “Pfizer continues to remain a leader in biologics and the application of new and emerging technologies to accelerate discovery to address patient needs. We are pleased to include OmniRat as part of our capabilities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics